Last reviewed · How we verify
EFAPROXIRAL
EFAPROXIRAL works by binding to and stabilizing hemoglobin, reducing the formation of methemoglobin and improving oxygen delivery to tissues.
EFAPROXIRAL is a small molecule drug in the efaproxiral class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown. EFAPROXIRAL has not been approved by the FDA for any indications, and its commercial status, including patent status and generic availability, is also unknown. As a result, there is limited information available on its safety profile, pharmacokinetics, and clinical use. Further research is needed to determine the potential benefits and risks of EFAPROXIRAL.
At a glance
| Generic name | EFAPROXIRAL |
|---|---|
| Drug class | efaproxiral |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | discontinued |
Mechanism of action
Imagine your body's oxygen delivery system like a delivery truck. EFAPROXIRAL helps fix a problem with the truck's cargo, allowing it to carry more oxygen to where it's needed. This can be especially important in situations where oxygen levels are low, such as during certain medical treatments.
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer (PHASE2)
- Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases (PHASE3)
- MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806 (NA)
- Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma (PHASE1,PHASE2)
- Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer (PHASE3)
- Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EFAPROXIRAL CI brief — competitive landscape report
- EFAPROXIRAL updates RSS · CI watch RSS